| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
90,630,000 |
| Market
Cap: |
14.57(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$129.52 - $244.6 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 664 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile BeiGene is a commercial-stage biotechnology company focused on developing and commercializing molecularly-targeted and immuno-oncology cancer therapeutics. Co.'s clinical-stage drug candidates include: Zanubrutinib, which is a small molecule inhibitor of Bruton's tyrosine kinase for the treatment of mantle cell lymphoma in adult patients; Tislelizumab, which is a humanized monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1; Pamiparib (BGB-290), which is for the treatment of various solid tumors; and Lifirafenib, which is an investigational small molecule inhibitor with RAF monomer and dimer inhibition activities.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
100,397 |
100,397 |
5,364,251 |
5,588,274 |
| Total Sell Value |
$15,909,372 |
$15,909,372 |
$1,039,781,980 |
$1,085,894,829 |
| Total People Sold |
2 |
2 |
8 |
9 |
| Total Sell Transactions |
6 |
6 |
20 |
54 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Wang Xiaodong |
Chair, Scientific Advisory Brd |
– • – |
2019-11-15 |
4 |
AS |
$202.05 |
$302,267 |
D/D |
(1,496) |
0 |
|
- |
|
| Wang Xiaodong |
Chair, Scientific Advisory Brd |
– • – |
2019-11-14 |
4 |
AS |
$193.57 |
$504,242 |
I/I |
(2,605) |
395 |
|
- |
|
| Wang Xiaodong |
Chair, Scientific Advisory Brd |
– • – |
2019-11-14 |
4 |
AS |
$191.03 |
$1,643,880 |
D/D |
(8,504) |
1,496 |
|
- |
|
| Wang Xiaodong |
Chair, Scientific Advisory Brd |
– • – |
2019-11-13 |
4 |
A |
$0.00 |
$0 |
I/I |
50 |
50 |
|
- |
|
| Wang Xiaodong |
Chair, Scientific Advisory Brd |
– • – |
2019-11-13 |
4 |
AS |
$0.00 |
$0 |
I/I |
(50) |
4,903,998 |
|
- |
|
| Chen Timothy Yung-Cheng |
Director |
– • – |
2019-11-05 |
4 |
AS |
$187.38 |
$718,772 |
D/D |
(3,800) |
200 |
|
- |
|
| Chen Timothy Yung-Cheng |
Director |
– • – |
2019-11-05 |
4 |
OE |
$41.01 |
$164,040 |
D/D |
4,000 |
4,000 |
|
- |
|
| Chen Timothy Yung-Cheng |
Director |
– • – |
2019-11-04 |
4 |
AS |
$189.37 |
$800,073 |
D/D |
(4,200) |
0 |
|
- |
|
| Chen Timothy Yung-Cheng |
Director |
– • – |
2019-11-04 |
4 |
OE |
$41.01 |
$164,040 |
D/D |
4,000 |
4,000 |
|
- |
|
| Huang Jane |
CMO, Hematology |
• – – |
2019-11-04 |
4 |
AS |
$189.08 |
$6,266,007 |
D/D |
(32,900) |
0 |
|
- |
|
| Huang Jane |
CMO, Hematology |
• – – |
2019-11-04 |
4 |
OE |
$29.49 |
$970,221 |
D/D |
32,900 |
32,900 |
|
- |
|
| Wang Xiaodong |
Chair, Scientific Advisory Brd |
– • – |
2019-11-04 |
4 |
AS |
$190.00 |
$190,000 |
D/D |
(1,000) |
0 |
|
- |
|
| Wang Xiaodong |
Chair, Scientific Advisory Brd |
– • – |
2019-11-01 |
4 |
AS |
$170.00 |
$170,000 |
D/D |
(1,000) |
0 |
|
- |
|
| Wu Xiaobin |
President & GM China |
• – – |
2019-11-01 |
4 |
AS |
$180.00 |
$180,000 |
D/D |
(1,000) |
0 |
|
- |
|
| Huang Jane |
CMO, Hematology |
• – – |
2019-09-04 |
4 |
AS |
$129.40 |
$10,611 |
D/D |
(82) |
0 |
|
- |
|
| Huang Jane |
CMO, Hematology |
• – – |
2019-09-03 |
4 |
AS |
$144.41 |
$413,420 |
D/D |
(2,862) |
0 |
|
- |
|
| Chen Timothy Yung-Cheng |
Director |
– • – |
2019-08-23 |
4 |
AS |
$143.01 |
$1,248,680 |
D/D |
(8,614) |
0 |
|
- |
|
| Chen Timothy Yung-Cheng |
Director |
– • – |
2019-08-23 |
4 |
OE |
$31.59 |
$249,561 |
D/D |
7,900 |
7,900 |
|
- |
|
| Glazer Donald W. |
Director |
– • – |
2019-08-12 |
4 |
D |
$0.00 |
$0 |
D/D |
(26,100) |
3,711,426 |
|
- |
|
| Glazer Donald W. |
Director |
– • – |
2019-08-12 |
4 |
D |
$0.00 |
$0 |
D/D |
(13,384) |
0 |
|
- |
|
| Huang Jane |
CMO, Hematology |
• – – |
2019-08-12 |
4 |
AS |
$132.47 |
$336,855 |
D/D |
(2,500) |
0 |
|
- |
|
| Huang Jane |
CMO, Hematology |
• – – |
2019-08-12 |
4 |
OE |
$45.31 |
$113,275 |
D/D |
2,500 |
2,500 |
|
- |
|
| Huang Jane |
CMO, Hematology |
• – – |
2019-07-29 |
4 |
AS |
$132.83 |
$1,362,896 |
D/D |
(10,130) |
0 |
|
- |
|
| Huang Jane |
CMO, Hematology |
• – – |
2019-07-29 |
4 |
OE |
$29.49 |
$377,834 |
D/D |
10,130 |
10,130 |
|
- |
|
| Oyler John |
Chief Executive Officer |
• • – |
2019-07-08 |
4 |
AS |
$125.59 |
$394,055 |
D/D |
(3,106) |
0 |
|
- |
|
527 Records found
|
|
Page 14 of 22 |
|
|
1.40 (0.86%) 
